AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...
Medpage Today on MSN2d
Herpes and Alzheimer's Tau; Dementia and Autism; Extended Paxlovid for Long COVIDA study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, ...
Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
Zacks.com on MSN2d
Denali's ALS Study Fails to Meet Primary and Secondary EndpointsDNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II ...
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.According ...
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback